EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ NSCLC
| Publication Date: |
2018-01-25
|
|---|---|
| Publisher: |
Wiley-Blackwell
|
| Print ISSN: |
0020-7136
|
| Electronic ISSN: |
1097-0215
|
| Topics: |
Biology
Medicine
|
| Published by: |